Keywords
How to Cite
Abstract
Diabetic nephropathy occurs in 20-45% of patients with diabetes mellitus. It is a specific renal damage in diabetes, leading to the formation of nodular or diffuse glomerulosclerosis, terminal stage is characterized by the development of chronic renal failure. Hyperglycemia, arterial hypertension, and dyslipidemia are the most important risk factors of this complication. The review is devoted to a role of glycemic control in the development and progression of diabetic nephropathy. Now it is established that tight metabolic control is the most effective means of nephroprotection in both types of diabetes. The HbA1c value is lower, the risk of development of a microalbuminuria is lower. Today any other medical intervention isn’t as effective as improvement of metabolic control in primary prevention of a diabetic nephropathy. Intensive glycemic control to prevent the development of diabetic nephropathy and its inhibition of progression involves achieving the target level HbA1с<7%, irrespective of the presence or absence of chronic kidney disease. To achieve the target level of glucose control clearly defined trend of switching patients on insulin therapy.
References
2. Головач І.Ю., Дячек О.В. Мікросудинні ускладнення цукрового діабету 2-го типу: необхідність інтенсивного контролю гіперглікемії // Практикуючий лікар. — 2015. — № 3. — С. 21-26.
3. Доскина Е.В. Диабетическая нефропатия. Фокус на раннюю диагностику и терапию // Эффективная фармакотерапия. — 2015. — № 28. — С. 24-31.
4. Недосугова Л.В. Значение гликемического контроля в профилактике диабетической нефропатии при сахарном диабете типа 2 // Трудный пациент. — 2013. — № 11 (5). — С. 26-31.
5. Скалий Н.Н. Медикаментозная коррекция диа бетической нефропатии на стадии гиперфильтрации // Почки. — 2016. — № 1 (15). — С. 71-73.
6. Шестакова М.В. Диабетическая нефропатия: фатальное или предотвратимое осложнение? // РМЖ. — 2001. — № 24. — С. 1095-1099.
7. Bakris G.L. Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus // Mayo Clin. Proc. — 2011. — V. 86 (5). — P. 444-456.
8. Bangstad H.J., Osterby R., Dahl-Jorgensen K., Berg K.J., Hartmann A., Hanssen K.F. Improvement of blood glucose control in IDDM patients retards progression of morphologic changes in early diabetic nephropathy // Diabetologia. — 1994. — V. 34. — P. 483-490.
9. Barbosa J., Steffes M.W., Sutherland D.E.R. et al. The effect of glycemic control on early diabetic renal lesions. A 5-year randomized controlled clinical trial of insulin-dependent diabetic kidney transplant recipients // JAMA. — 1994. — V. 272. — P. 600-606.
10. Bojestig M., Arnqvist H.J., Karlberg B.E., Ludgvisson J. Glycemic control and prognosis in type 1 diabetic patients with microalbuminuria // Diabetes Care. — 1996. — V. 19. — P. 313-317.
11. Caramori M.L., Fioretto P., Mauer M. Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: an indicator of more advanced glomerular lesions // Diabete. — 2003. — V. 52. — P. 1036-1040.
12. Diabetes Complications and Control Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications of insulin dependent diabetes mellitus // N. Engl. J. Med. — 1993. — V. 329. — P. 977-986.
13. Felt-Rasmussen B., Mathiesen E.R., Deckert T. Effect of two years of strict metabolic control on progression of incipient nephropathy in insulindependent
diabetes // Lancet. — 1986. — V. 2. — P. 1300-1304.
14. Fioretto P., Bruseghin M., Berto I. et al. Renal Protection in Diabetes: Role of Glycemic Control // JASN. — 2006. — V. 17 (4). — P. 86-89.
15. Gorris J.L., Nieto J., Navarro-Gonzales J.F. et al. Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data? // J. Clin. Med. — 2015. — V. 4 (10). — P. 1866-89.